Suppr超能文献

急性冠状动脉综合征的不同临床结局:药物涂层球囊血管成形术治疗患者中糖尿病风险的增加

Differential clinical outcomes in ACS: the amplified risk of diabetes in patients treated with drug-coated balloon angioplasty.

作者信息

Khaled Sheeren, Khouj Saleh, Ismail Mamdouh, Ebrahim Ahmed, Shalaby Ghada, Sheikh Anas, Ujami Abdullatif, Elsheikh Mohamed, Sadhiq Mohammed, Darwish Ahmed

机构信息

King Abdullah Medical City, Makkah al Mukarramah, Saudi Arabia.

Benha University, Banhā, Egypt.

出版信息

Egypt Heart J. 2025 Sep 12;77(1):87. doi: 10.1186/s43044-025-00686-4.

Abstract

BACKGROUND

Emerging evidence supports drug-coated balloons (DCBs) as a compelling alternative to stent-based interventions in acute coronary syndrome (ACS), particularly in diabetic populations where lesion complexity and metabolic dysfunction often undermine long-term outcomes. This study explores real-world safety and efficacy of DCB-only angioplasty in ACS patients, with focused analysis of diabetic subgroups.

METHODS

A single-center, retrospective cross-sectional analysis was conducted at King Abdullah Medical City between 2019 and 2023. The study enrolled patients presenting with ACS who underwent DCB treatment during this period.

RESULTS

Of 212 patients, 55% had diabetes mellitus. Diabetic individuals exhibited significantly higher comorbid burden-hypertension, dyslipidemia, and prior coronary interventions. Non-ST-elevation myocardial infarction (NSTEMI) predominated among diabetics, and in-stent restenosis (ISR) was more frequently observed than de novo lesions. At one-month follow-up, diabetic patients experienced marginally fewer major adverse cardiovascular events (MACE) than non-diabetics; however, parity was observed at one year. Within the diabetic group, insulin therapy and suboptimal glycemic control (HbA1c > 8.0%) were strongly associated with increased 12-month cardiovascular risk, particularly due to repeat revascularization. Importantly, neither clinical presentation nor angiographic features predicted these risks. Instead, elevated HbA1c and reduced left ventricular ejection fraction (LVEF) independently forecasted adverse outcomes post-DCB.

CONCLUSION

In the context of ACS, diabetic patients remain uniquely vulnerable. Metabolic control and cardiac function-not anatomy alone-emerge as decisive prognostic factors after DCB therapy. Despite inherent challenges, DCB offers a targeted and promising revascularization approach when patient-specific risk modifiers are proactively addressed.

摘要

背景

新出现的证据支持药物涂层球囊(DCB)作为急性冠状动脉综合征(ACS)中基于支架干预的一种有吸引力的替代方案,特别是在糖尿病患者中,病变复杂性和代谢功能障碍常常会影响长期预后。本研究探讨单纯DCB血管成形术在ACS患者中的真实世界安全性和有效性,并重点分析糖尿病亚组。

方法

2019年至2023年在阿卜杜拉国王医疗城进行了一项单中心回顾性横断面分析。该研究纳入了在此期间接受DCB治疗的ACS患者。

结果

在212例患者中,55%患有糖尿病。糖尿病患者的合并症负担(高血压、血脂异常和既往冠状动脉干预)明显更高。糖尿病患者中非ST段抬高型心肌梗死(NSTEMI)占主导,与新发病变相比,支架内再狭窄(ISR)更常见。在1个月的随访中,糖尿病患者发生的主要不良心血管事件(MACE)略少于非糖尿病患者;然而,在1年时观察到二者相当。在糖尿病组中,胰岛素治疗和血糖控制不佳(糖化血红蛋白>8.0%)与12个月心血管风险增加密切相关,尤其是由于再次血运重建。重要的是,临床表现和血管造影特征均不能预测这些风险。相反,糖化血红蛋白升高和左心室射血分数(LVEF)降低独立预测了DCB术后的不良结局。

结论

在ACS背景下,糖尿病患者仍然特别脆弱。代谢控制和心脏功能而非仅仅解剖结构成为DCB治疗后决定性的预后因素。尽管存在固有挑战,但当针对患者的风险修正因素得到积极处理时,DCB提供了一种有针对性且有前景的血运重建方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e20/12431977/8b082e77c3dc/43044_2025_686_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验